CUBE's goal is to push the envelope on innovation. Making change and innovation happen in the industry is a tough challenge that takes knowledge, creativity, time and also courage. No Equity. No obligations. No strings attached. If your startup is outstanding, your products are desperately needed by the industry and the best of all qualifiers, CUBE will give you one million euros in cash.

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the fourth quarter and full year of 2016, which were highlighted by strong sales for key products Opdivo and Eliquis, regulatory approvals for Opdivo in the U.S. and Europe, and strategic transactions in oncology and fibrosis that further strengthened the company's pipeline.

AstraZeneca today announced that on 25 January 2017 the US Food and Drug Administration (FDA) granted six months of paediatric exclusivity for Symbicort (budesonide/formoterol) Inhalation Aerosol. The FDA's decision was based on the evaluation of trials conducted in children with asthma aged six up to 12 years in response to a Written Request

Abbott (NYSE: ABT) has announced that fourth-quarter 2016 worldwide sales of $5.3 billion increased 2.8 percent on a reported basis, including an unfavorable 1.0 percent effect of foreign exchange, and increased 3.8 percent on an operational basis. Full-year 2016 worldwide sales increased 2.2 percent on a reported basis and 4.8 percent on an operational basis.

Novartis announced today that the net sales were USD 48.5 billion (-2%, 0% cc) in the full year, as volume growth of 6 percentage points was offset by the negative impact of generic competition (-4 percentage points) and pricing (-2 percentage points). Growth Products contributed USD 17.1 billion or 35% of net sales, up 20% (USD) over the prior year.

AstraZeneca has provided an update on its Immuno-Oncology (IO) late-stage clinical development programme in 1st-line non-small cell lung cancer (NSCLC), including a refinement of the Phase III MYSTIC trial. The MYSTIC trial was initially designed to assess the benefit of durvalumab monotherapy and durvalumab and tremelimumab (durva + treme) combination therapy versus

Merck, a leading science and technology company, today announced it has entered into a collaboration and licensing agreement with Domain Therapeutics, Strasbourg, France, to explore the potential of adenosine inhibition in the development of novel immuno-oncology agents. This collaboration strengthens the combination strategy in immuno-oncology, and underscores Merck's science-driven approach to discovering and developing novel compounds through both internal capabilities and external collaborations.